Shares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...

Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...

CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company with a market capitalization of $59.31 million, has entered into a clinical supply agreement with Regeneron ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

Conversely, the Conference Board’s US Jan consumer confidence index unexpectedly fell -5.4 to a 4-month low of 104.1, weaker than expectations of 105.7. The markets expect the FOMC to keep the fed ...

IMM-1-104 combined with mGnP shows promising efficacy and tolerability in first-line pancreatic cancer, with a 43% ORR and 86% DCR among seven patients. IMM-1-104 demonstrated target lesion shrinkage ...

The US Jan Philadelphia Fed business outlook survey jumped 55.2 to a 3-3/4 year high of 44.3, stronger than expectations of -5.0. The US Dec import price index ex-petroleum unexpectedly rose +0.2% m/m ...

Copyright 2025 The Associated Press. All Rights Reserved. Toronto Raptors forward Scottie Barnes (4) and Golden State Warriors forward Gui Santos (15) vie for control ...

“We are thrilled to report two more responses in our Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX in first-line pancreatic cancer,” said Ben Zeskind, Ph.D., CEO of ...

Immuneering Corp (NASDAQ:IMRX), a biopharmaceutical company focusing on drug development with a market capitalization of $63.34 million, has announced promising interim data from its ongoing Phase 2a ...

(RTTNews) - Immuneering Corporation (IMRX), a Massachusetts-based biopharmaceutical company Monday announced a positive update from its Phase 2a study of IMM-1-104 combined with modified ...